

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**CanSino Biologics Inc.**  
**康希諾生物股份公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 6185)**

**INSIDE INFORMATION**  
**EMERGENCY USE LISTING FOR CONVIDECIA RECEIVED**  
**FROM WORLD HEALTH ORGANIZATION**

This announcement is made by CanSino Biologics Inc. (the “**Company**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

The Company is pleased to announce that, as announced by the World Health Organization (the “**WHO**”), the Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (trade name: Convidecia) (the “**Convidecia**”) has been issued an emergency use listing of the WHO (the “**EUL**”). Convidecia was assessed using the process as described in the WHO EUL procedure. This decision of WHO is based on the review of data on quality, safety, efficacy and a risk management plan by WHO Prequalification experts including regulatory experts from around the world. The final risk benefit assessment was conducted by the Technical Advisory Group for EUL. It has determined that the vaccine meets WHO standards for protection against COVID-19 and that the benefits of the vaccine far outweigh risks. For details, please refer to <https://www.who.int/news/item/19-05-2022-who-validates-11th-vaccine-for-covid-19>.

Convidecia is a genetically engineered vaccine with the replication-defective adenovirus type 5 vector expressing the SARS-CoV-2 coronavirus spike protein. Convidecia does not contain preservatives, adjuvants nor substances of animal origin. EUL is a prerequisite for COVID-19 Vaccines Global Access (COVAX) vaccine supply. It also allows countries to expedite their own regulatory approval to import and administer COVID-19 vaccines.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**CanSino Biologics Inc.**  
**Xuefeng YU**  
*Chairman*

Hong Kong, May 20, 2022

*As of the date of this announcement, the board of directors comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU, Dr. Dongxu QIU and Ms. Jing WANG as executive directors, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive directors.*